Inovio Stock Soars Following FDA Approval for Rare Respiratory Disease Immunotherapy
Inovio stock surges after FDA accelerated approval of Voceryq, an immunotherapy reducing surgeries for adults with recurrent respiratory papillomatosis.
Inovio got FDA approval for a new medicine that helps people with a rare disease. When companies get approval for new medicines, it shows their work is working and people trust them more.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.